Enliven Therapeutics (ELVN) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 24, 2025, to be held virtually for stockholders of record as of April 25, 2025.

• Proxy materials, including the notice, proxy statement, and annual report, are available online or by request.

Voting matters and shareholder proposals

• Election of three Class II directors to serve until the 2028 annual meeting or until successors are qualified.

• Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.

• Authorization for proxies to vote on any other business that may properly come before the meeting.

Board of directors and corporate governance

• Board recommends voting FOR the election of Rahul D. Ballal, Ph.D., Jake Bauer, M.B.A, and Andrew Phillips, Ph.D. as Class II directors.